Cardlytics Bilan de santé
Santé financière contrôle des critères 2/6
Cardlytics possède un total de capitaux propres de $-6.5M et une dette totale de $208.9M, ce qui porte son ratio d'endettement à -3210.2%. Son actif total et son passif total sont $285.6M et de $292.1M.
Informations clés
-3,210.20%
Ratio d'endettement
US$208.92m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$48.72m |
| Fonds propres | -US$6.51m |
| Total du passif | US$292.15m |
| Total des actifs | US$285.64m |
Mises à jour récentes de la santé financière
Article d'analyse • Jul 05
Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Mar 11
Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d'analyse • Oct 15
Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d'analyse • Jan 04
Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Oct 05
We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Recent updates
Mise à jour de l'analyse • May 01
CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing
Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
Mise à jour de l'analyse • Apr 17
CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential
Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.Mise à jour de l'analyse • Apr 03
CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing
Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.Mise à jour de l'analyse • Mar 20
CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential
Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.Mise à jour de l'analyse • Mar 06
CDLX: Reset Expectations And CFO Return Will Support Future Rerating
Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.Article d'analyse • Jan 08
Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...Seeking Alpha • Oct 06
Cardlytics: Debt Overhang Casts Shadow On Upside
Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking AlphaMise à jour de l'analyse • Aug 08
Bank Partnerships And Data-Driven Marketing Will Shape Future Markets
The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.Article d'analyse • Jul 23
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%
Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...Article d'analyse • Jul 05
Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • May 29
Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Article d'analyse • Apr 07
Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge
Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
Nouvelle analyse • Apr 03
US Neobank And Taiwan Office Will Unlock New Markets
Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.Article d'analyse • Mar 11
Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d'analyse • Feb 21
Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)
It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...Seeking Alpha • Feb 13
Cardlytics: Short-Term Headwinds Drive Long-Term Success
Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking AlphaArticle d'analyse • Jan 10
At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?
Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...Seeking Alpha • Dec 07
Cardlytics Continues Revenue Contraction Amid Worsening Economics
Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking AlphaArticle d'analyse • Nov 23
Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...Article d'analyse • Nov 05
After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Article d'analyse • Oct 15
Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 17
Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)
Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking AlphaArticle d'analyse • Aug 09
Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk
Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • Jul 02
Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain
Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking AlphaArticle d'analyse • May 31
Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...Seeking Alpha • Apr 17
The Power Of Cardlytics' Data Partnerships Including Bank of America
Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking AlphaArticle d'analyse • Apr 10
Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors
Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...Seeking Alpha • Feb 16
Cardlytics: Good Prospects But Macro Uncertain
Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking AlphaArticle d'analyse • Jan 18
Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...Article d'analyse • Jan 04
Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Oct 05
We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse de la situation financière
Passif à court terme: CDLX a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.
Passif à long terme: CDLX a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.
Historique et analyse du ratio d'endettement
Niveau d'endettement: CDLX a des fonds propres négatifs, ce qui est une situation plus grave qu'un niveau d'endettement élevé.
Réduire la dette: CDLX a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: CDLX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: CDLX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 0.3 % chaque année
Découvrir des entreprises saines
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/07 05:50 |
| Cours de l'action en fin de journée | 2026/05/07 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cardlytics, Inc. est couverte par 12 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Omar Dessouky | BofA Global Research |
| Jason Kreyer | Craig-Hallum Capital Group LLC |
| Robert Coolbrith | Evercore ISI |